Jazz Pharmaceuticals (NASDAQ:JAZZ) used an investor call following the ASCO Gastrointestinal Cancer Symposium to highlight ...
Jazz Pharmaceuticals reported Phase 3 trial results showing Ziihera helped patients with advanced HER2-positive stomach ...
Jazz’s Ziihera and BeOne’s Tevimbra plus chemotherapy led to what Truist Securities dubbed one of the strongest overall ...
Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz ...
Ireland-headquartered Jazz Pharmaceuticals closed Tuesday’s trading 4% lower despite announcing positive efficacy and safety ...
OKC Thunder Wire on MSN
Mark Daigneault offers injury update on Jaylin Williams' heel bursitis
Williams has missed 12 straight games with heel bursitis. He last played in the 2025 NBA Cup semifinals on Dec. 13 in a loss ...
Saxophonist Kate Olson is releasing "So It Goes" in January, her first full-length studio album under her own name.
The creative team behind Chloé Zhao’s “Hamnet” gathered for a panel discussion as part of the Variety Screening Series to ...
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® (zanidatamab-hrii) in combination with ...
Chris Connor chats with Is This Thing On? composer James Newberry… Bradley Cooper’s third feature as a director, Is This ...
On January 11, 1997, Robert Horry, recently suspended for throwing a towel in the face of Suns head coach Danny Ainge while ...
Investing.com -- Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) stock fell 4.5% on Tuesday after the company announced positive Phase 3 trial results for its cancer drug Ziihera that showed mixed benefits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback